![Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement]()
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statementGoldsmith, D.; Covic, A.; Vervloet, M.; Cozzolino, M.; Nistor, I.; Chronic Kidney Disease-Mineral Bone Disease, ; Cozzolino, M.; Vervloet, M.; Brandenburg, V.; Bover, J.; Covic, A.; Evenepoel, P.; Goldsmith, D.; Massy, Z.; Mazzaferro, S.; Urena-Torres, P.; Abramowicz, D.; Bolignano, D.; Cannata Andia, G.; Cochat, P.; Covic, A.; Delvecchio, L.; Drechsler, C.; Eckardt, K. U.; Fouque, D.; Fox, J.; Haller, M.; Heimburger, O.; Jager, K. J.; Lindley, E.; Marti Monros, A. M.; Nagler, E.; Oberbauer, R.; Spasovski, G.; Tattersall, J.; Van Biesen, W.; vander Veer, S.; Vanholder, R.; Wanner, C.; Wheeler, D.; Whithers, W.; Wiecek, A.; Zoccali, C. · Nephrology Dialysis Transplantation · 2015